Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Gross Margin (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Gross Margin readings, the most recent being 90.29% for Q1 2026.

  • On a quarterly basis, Gross Margin rose 326.0% to 90.29% in Q1 2026 year-over-year; TTM through Mar 2026 was 89.31%, a 348.0% increase, with the full-year FY2025 number at 88.54%, up 293.0% from a year prior.
  • Gross Margin hit 90.29% in Q1 2026 for Kiniksa Pharmaceuticals International, up from 89.64% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 104.52% in Q4 2022 to a low of 81.35% in Q2 2022.
  • Median Gross Margin over the past 5 years was 88.51% (2023), compared with a mean of 89.16%.
  • The widest YoY moves for Gross Margin: up 1588bps in 2022, down -1894bps in 2022.
  • Kiniksa Pharmaceuticals International's Gross Margin stood at 104.52% in 2022, then dropped by -15bps to 88.51% in 2023, then dropped by -4bps to 85.4% in 2024, then grew by 5bps to 89.64% in 2025, then rose by 1bps to 90.29% in 2026.
  • The last three reported values for Gross Margin were 90.29% (Q1 2026), 89.64% (Q4 2025), and 88.8% (Q3 2025) per Business Quant data.